Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update.
Honglei RenRanran HanXuemei ChenXi LiuJieru WanLimin WangXiuli YangJian WangPublished in: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2020)
Intracerebral hemorrhage (ICH) is a subtype of stroke with high mortality and disability but no specific or effective treatment. In the last two decades, much has been learned about the pathologic mechanisms of ICH. It is now known that after ICH onset, immune and inflammatory responses contribute to blood-brain barrier disruption, edema development, and cell death processes, jointly resulting in secondary brain injury. However, the translation of potential therapies from preclinical to clinical success has been disappointing. With the development of new laboratory technology, recent progress has been made in the understanding of ICH pathomechanisms, and promising therapeutic targets have been identified. This review provides an update of recent progress on ICH and describes the prospects for further preclinical studies in this field. Our goal is to discuss new therapeutic targets and directions for the treatment of ICH and promote the effective transformation from preclinical to clinical trials.
Keyphrases
- brain injury
- blood brain barrier
- cerebral ischemia
- subarachnoid hemorrhage
- cell death
- clinical trial
- cell therapy
- multiple sclerosis
- oxidative stress
- atrial fibrillation
- stem cells
- cardiovascular events
- combination therapy
- radiation therapy
- coronary artery disease
- squamous cell carcinoma
- climate change
- mesenchymal stem cells
- risk factors
- lymph node
- study protocol
- cell proliferation